Though paxlovid usually prevents hospital stays it also often creates "rebound" positives as well

In addition to Biden this also happened to a friend of mine who took the Paxlovid early treatment to avoid a hospital stay so even though when you rebound you often have no symptoms it has to do with the way the body's own defenses are kicking into action beyond the Paxlovid that causes this response. I think my friend had to keep away from people about 3 weeks or more to protect others from infection while he was testing positive and this effect could last up to one month that you need to be away from others and might still be testing positive with no real symptoms.

The problem with this is people don't run on Paxlovid they run on money and for less wealthy people there will be the temptation to say that they are negative when they are still positive and potentially infectious just so they can earn a living which could spread the BA 4 and BA5 much further than it presently is and create problems for many many people worldwide. 

However, the most important thing here is that Paxlovid will tend to keep you out of the hospital which is probably the most important thing here.

Also, my wife has a different opinion which is that the number of days a person might test positive is speculative on my part.

However, I can only report what I'm relatively sure of and she might be privy to other information that I am not aware of?

My wife thinks my friend was testing positive for 18 days which is less than 3 weeks but more than 2 weeks. However, I believe one could test positive from Paxlovid up to 1 month presently.

The people that need most to be taking paxlovid after a positive test are those over 45 or 50 and those who have serious health conditions of any age. I think it is a 5 day course of medicine?

Here is what the makers of Paxlovid say:

begin quote from: https://www.paxlovidhcp.com/dosing?source=google&HBX_PK=s_paxlovid+schedule&skwid=43700068281649206&gclid=Cj0KCQjw0JiXBhCFARIsAOSAKqA3lmE7mVEPiOFisZzIqPoI4akfGhwUBGmZBAXXY0qfEdmIslyJ5UAaAqJPEALw_wcB&gclsrc=aw.ds

​​​​​​​Authorized Use

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Limitations of Authorized Use

• PAXLOVID is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19
• PAXLOVID is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19
• PAXLOVID is not authorized for use for longer than 5 consecutive days

​​​​​​​​​​​​​​PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which PAXLOVID belongs (i.e., anti-infectiv